Skip to content
Screener

BridgeBio Pharma BBIO Net product revenue — Revenue

Other product segments

Cost of license, services, and royalty revenue
$10.3M—
License and services revenue
$4.42M—

Similar metrics at other companies

Syndax Pharmaceuticals logo
SNDXNet Product Revenues — Revenue
$31.21M+1,526%
Kopin logo
KOPNNet Product Revenues — Revenue
$5.42M-41.2%
GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%
Itron logo
ITRIProduct revenues — Revenue
$453.46M-12.3%
CPR
CPRXProduct Revenue Net — Revenue
$149.34M+5.6%
Kopin logo
KOPNNet Product Revenue — Revenue
$5.42M-41.2%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001743881-26-000019
Line itemThree Months Ended March 31, 20262025
Revenues:
Net product revenue$180,596$36,739
License and services revenue4,41979,690
Royalty revenue9,500204
Total revenues, net194,515116,633
Operating costs and expenses:
Cost of revenues:
Cost of goods sold7,7322,034

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's net product revenue — revenue?
BridgeBio Pharma (BBIO) reported net product revenue — revenue of $180.6M in Q1 2026.
How has BridgeBio Pharma's net product revenue — revenue changed year-over-year?
BridgeBio Pharma's net product revenue — revenue increased by 391.6% year-over-year, from $36.74M to $180.6M.
What is the long-term trend for BridgeBio Pharma's net product revenue — revenue?
Over 2 years (2021 to 2025), BridgeBio Pharma's net product revenue — revenue has grown at a 877.5% compound annual growth rate (CAGR), from $3.79M to $362.4M.
What does net product revenue — revenue mean?
This metric represents the total gross income generated from the sale of pharmaceutical products within a specific business segment. It reflects the commercial success of the company's therapeutic pipeline as products transition from clinical development to market availability. This figure is a primary indicator of the company's ability to monetize its genetic disease and oncology treatments.

Ask your AI about BridgeBio Pharma's net product revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude